Skip to main content
SpringerLink
Log in

Analyse prognostischer Faktoren beim Plasmozytom

Analysis of prognostic factors in multiple myeloma

  • Originalien
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

For analysis of prognostic factors the clinical course of 109 patients with multiple myeloma was evaluated. Survival curves of immunoglobulin (Ig)G- and IgA-myelomas were identical (Fig. 1) with median survival times of 52 and 42 months, respectively, whereas patients with IgD- and Bence-Jones-myeloma had short survival times (median 3 months). Most important risk factors were anemia, renal insufficiency, and hypercalcemia (Figs. 7 and 8). Median survival time dropped from 52 months (Hb above 100 g/l) to 22 (Hb 85–100 g/l) and 1 month (Hb below 85 g/l). Patients with serum creatinine values below 2 mg/dl lived significantly longer than those with values above. Median survival times were 52 and 1 month, respectively. All seven hypercalcemic patients had a renal insufficiency and were in a very poor condition; their median survival time was 1 month. Analysis of the widely used staging system of Durie and Salmon [16] gave disappointing results. Survival curves of the three A-stages ran close together with median survival times of 58, 51, and 36 months. Only the A-B classification according to renal function (A: creatinine under 2 mg/dl; B: creatinine above 2 mg/dl) proved prognostically relevant.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literatur

  1. Acute Leukemia Group B (1975) Correlation of abnormal immunoglobin with clinical features of myeloma. Arch Intern Med 135:46–52

    Google Scholar 

  2. Alexanian R (1980) Localized and indolent myeloma. Blood 56:521

    Google Scholar 

  3. Alexanian R, Balcerzak S, Bonnet JD, Gehan EA, Haut A, Hewlett JS, Monto RW (1975) Prognostic factors in multiple myeloma. Cancer 36:1192–1201

    Google Scholar 

  4. Belpomme D, Simon F, Pouillart P, Amor B, Feuilhade de Chauvin F, Belpomme A, Menkes C, Delrieu A, Depierre R, Le Mevel B, Serrou B, Fries D, Delbarre F, Mathé G (1978) Prognostic factors and treatment of multiple myeloma: Interest of a cyclic sequential chemohormonotherapy combining cyclophosphamide, melphalan, and prednisone. In: Mathé G, Seligman M, Tubiana M (eds) Recent results in cancer research. Lymphoid neoplasias. II. Clinical and therapeutic aspects. Springer, Berlin Heidelberg New York, p 28–40

    Google Scholar 

  5. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB (1979) The chemotherapy of plasmacell myeloma and the incidence of acute leukemia. N Engl J Med 301:743–748

    Google Scholar 

  6. Bergsagel DE, Migliore PJ, Griffith KM (1965) Myeloma proteins and the clinical response to melphalan therapy. Science 148:376–377

    Google Scholar 

  7. Bergsagel DE, Pruzanski W (1975) Treatment of plasma cell myeloma with cytotoxic agents. Arch Intern Med 135:172–176

    Google Scholar 

  8. Buckman R, Cuzick J, Galton DAG (1982) Long-term survival in myelomatosis. Brit J Haematol 52:589–599

    Google Scholar 

  9. Carbone PP, Kellerhouse LE, Gehan EA (1967) Plasmocytic myeloma. Amer J Med 42:937–948

    Google Scholar 

  10. Child JA, Crawford SM, Norfolk DR, O'Quigley J, Scarffe JH, Struthers LPL (1983) Evaluation of serum β2-microglobulin as a prognostic indicator in myelomatosis. Brit J Cancer 47:111–114

    Google Scholar 

  11. Cohen HJ, Silberman HR, Larsen WE, Johnson L, Bartolucci AA, Durant JR (1979) Combination chemotherapy with intermittent 1-3-bis-(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma. Blood 54:824–836

    Google Scholar 

  12. Costa G, Engle RL jr, Schilling A, Carbone P, Kochwa S, Nachman RL, Glidewell O (1973) Melphalan and prednisone: An effective combination for the treatment of multiple myeloma. Amer J Med 54:589–599

    Google Scholar 

  13. Costa G, Engle RL jr, Taliente P (1969) Criteria for defining risk groups and response to chemotherapy in multiple myeloma. Proc Amer Assoc Cancer 10:15

    Google Scholar 

  14. Dawson AA, Ogston D (1971) Factors influencing the prognosis in myelomatosis. Postgrad Med J 47:635–638

    Google Scholar 

  15. Durie BGM, Cole PW, Chen HSG, Himmelstein KJ, Salmon SE (1981) Synthesis and metabolism of Bence Jones protein and calculation of tumour burden in patients with Bence Jones myeloma. Brit J Haematol 47:7–19

    Google Scholar 

  16. Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842–854

    Google Scholar 

  17. Durie BGM, Salmon SE, Moon TE (1980) Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 55:364–372

    Google Scholar 

  18. Einhorn N (1978) Acute leukemia after chemotherapy (melphalan). Cancer 41:444–447

    Google Scholar 

  19. Feinleib M, MacMahon B (1960) Duration of survival in multiple myeloma. J Natl Cancer Inst 24:1259–1269

    Google Scholar 

  20. Fritz E, Radaszkiewicz T, Darda W, Ludwig H (1983) Klinisch-prognostische Relevanz des morphologischen Differenzierungsgrades beim multiplen Myelom. Verh Dtsch Ges Inn Med 89:1001–1005

    Google Scholar 

  21. Große Hokamp H, Grundman E (1983) Histological grading and clinical staging of plasmocytoma. J Cancer Res Clin Oncol 105:197–198

    Google Scholar 

  22. Guglielmo Di R, Vercelli D, Guidi G (1979) Lo staging clinico e quantitativo e il monitoraggio del mielomo multiplo. Rec Progr Med 66:382–417

    Google Scholar 

  23. Hansen OP, Drivsholm A (1982) Renal plasma clearance: a valuable marker in myelomatosis. Blut 45:1–11

    Google Scholar 

  24. Hansen OP, Jessen B, Videbaek A (1973) Prognosis of myelomatosis on treatment with prednisone and cytostatics. Scand J Haematol 10:282–290

    Google Scholar 

  25. Harley J, McIntyre OR, Pajak TF (1977) Improved survival of poor risk myeloma patients receiving combination alkylating agent therapy. Blood 50:Suppl 1:192

    Google Scholar 

  26. Harley JB, Pajak TF, McIntyre OR, Kochwa S, Cooper MR, Coleman M, Cuttner J (1979) Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB. Blood 54:13–21

    Google Scholar 

  27. Hobbs JR (1969) Growth rates and responses to treatment in human myelomatosis. Brit J Haematol 16:607–617

    Google Scholar 

  28. Hobbs JR (1975) Monitoring myelomatosis. Arch Intern Med 135:125–130

    Google Scholar 

  29. Hofmann V, Salmon SE, Durie BGM (1981) Drug resistance in multiple myeloma associated with high in vitro incorporation of3H-thymidine. Blood 58:471–476

    Google Scholar 

  30. Jacobs P, Dubovsky D, King HS (1975) Myeloma — the therapeutic dilemma. S Afr Med J 49:650–651

    Google Scholar 

  31. Jancelewicz Z, Takatsuki K, Sugai S, Pruzanski W (1975) IgD multiple myeloma: Review of 133 cases. Arch Intern Med 135:87–93

    Google Scholar 

  32. Jansen J, Huijgens PC, van der Velde EA (1980) The prognosis of multiple myeloma. Neth J Med 23:246–251

    Google Scholar 

  33. Johansson B (1971) Prognostic factors in myelomatosis. Brit Med J 2:327–328

    Google Scholar 

  34. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Amer Stat Assoc 53:457–481

    Google Scholar 

  35. Kiang DT, Goldman A, Fortuny I, Theologides A, Kennedy BJ (1973) Prognostic factors in multiple myeloma. Proc Am Assoc Cancer 14:107

    Google Scholar 

  36. Klener P, Donner L, Sak P, Strnad Z (1980) Prognostické faktory u plazmocytomu. Sbornik Lekasrky 10:331–336

    Google Scholar 

  37. Knolle J, Arnold W, Meyer zum Büschenfelde KH, Schäfer R, Mainzer K (1974) IgD-Plasmozytom und Amyloidose. Inn Med 1:28–43

    Google Scholar 

  38. Kyle RA, Greipp PR (1980) Smouldering multiple myeloma. N Engl J Med 302:1347–1349

    Google Scholar 

  39. Kyle RA, Elveback LR (1976) Management and prognosis of multiple myeloma. Mayo Clin Proc 51:751–760

    Google Scholar 

  40. Kyle RA, Pierre RV, Bayrd ED (1975) Multiple myeloma and acute leukemia associated with alkylating agents. Arch Intern Med 135:185–192

    Google Scholar 

  41. Lee BJ, Shakian G, Clarkson BD, Krakoff IH (1974) Combination chemotherapy of multiple myeloma with Alkeran, Cytoxan, Vincristine, prednisone, and BCNU. Cancer 33:533–538

    Google Scholar 

  42. Ludwig H (1982) Multiples Myelom. Springer, Berlin Heidelberg New York

    Google Scholar 

  43. Märki HH, Wuhrmann F, Largiadér A (1965) Zur prognostischen Beurteilung der Plasmozytomkrankheit. Schweiz med Wschr 95:585–589

    Google Scholar 

  44. Matzner Y, Benbassat J, Polliack A (1977) Prognostic factors and the effect of alkylating agents on survival in multiple myeloma. A review of 80 patients. Israel J Med Sci 13:797–807

    Google Scholar 

  45. Matzner Y, Benbassat J, Polliack A (1978) Prognostic factors in multiple myeloma. A retrospective study using conventional statistical methods and a computer program. Acta Haematol 60:257–268

    Google Scholar 

  46. Medical Research Council (1980) Prognostic features in the third MRC myelomatosis trial. Br J Cancer 42:831–840

    Google Scholar 

  47. Medical Research Council (1980) Report on the second myelomatosis trial after five years of follow-up. Br J Cancer 42:813–821

    Google Scholar 

  48. Merlini G, Waldenström JG, Jayakar SD (1980) A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood 55:1011–1019

    Google Scholar 

  49. Morell A, Skvaril F, Rüst HP, Spengler GA, Brunner K, Barandun S (1970) Zur Prognose des multiplen Myeloms. Schweiz med Wschr 100:1990–1992

    Google Scholar 

  50. Ösby E, Carlmark B, Reizenstein P (1978) Staging of myeloma. A preliminary study of staging factors and treatment in different stages. In: Mathé G, Seligman M, Tubiana M (Eds) Recent results in cancer research. Lymphoid neoplasias. II. Clinical and therapeutic aspects. Springer, Berlin Heidelberg New York, p 21–27

    Google Scholar 

  51. Osgood EE (1960) The survival time of patients with plasmocytic myeloma. Cancer Chemother Rep 9:1–10

    Google Scholar 

  52. Pankovich AM, Griem ML (1972) Plasma-cell myeloma. A thirty-year follow-up. Radiology 104:521–522

    Google Scholar 

  53. Payne RB, Little AJ, Williams RB, Milner JR (1973) Interpretation of serum calcium in patients with abnormal serum proteins. Brit J Med 4:643–646

    Google Scholar 

  54. Pennec Y, Mottier D, Youinou P, Asselain B, Chavance M, Le Goff P, Le Prise PY, Miossec P, Le Menn G (1983) Critical study of staging in multiple myeloma. Scand J Haematol 30:183–190

    Google Scholar 

  55. Rosner F, Grünwald H (1974) Multiple myeloma terminating in acute leukemia: Report of 12 cases and review of the literature. Amer J Med 57:927–939

    Google Scholar 

  56. Salmon SE (1973) Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Semin Hematol 10:135–147

    Google Scholar 

  57. Salmon SE, Smith BA (1970) Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J Clin Invest 49:1114–1121

    Google Scholar 

  58. Salmon SE, Wampler SB (1977) Multiple myeloma: Quantitative staging and assessment of response with a programmable pocket calculator. Blood 49:379–389

    Google Scholar 

  59. Shustik C, Bergsagel DE, Pruzanski W (1976) Kappa and Lambda light chain disease: survival rates and clinical manifestations. Blood 48:41–51

    Google Scholar 

  60. Southeastern Cancer Study Group (1975) Treatment of myeloma. Comparison of melphalan, chlorambucil, and azathioprine. Arch Intern Med 135:157–162

    Google Scholar 

  61. Vercelli D, Cozzolino F, di Guglielmo R (1981) A comparison of two staging systems for myeloma. Nouv Rev Fr Hematol. 23:107–110

    Google Scholar 

  62. Vercelli D, di Guglielmo R, Guidi G, Scolari L, Buricchi L, Cozzolino F (1980) Bone marrow percentage of plasma cells in the staging of monoclonal gammopathies. Nouv Rev Fr Hematol 22:139–145

    Google Scholar 

  63. Videbaek A, Johansen H (1956) Prognosis in eighty cases of multiple myeloma. Dan med Bull 3:174–176

    Google Scholar 

  64. Woodruff RK, Wadsworth J, Malpas JS, Tobias JS (1979) Clinical staging in multiple myeloma. Brit J Haemat 42:199–205

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. II. Medizinische Klinik und Poliklinik der Universität Kiel, Germany

    W. Gassmann, T. Haferlach, N. Schmitz, W. Kayser, H. H. Euler, J. Drews & H. Löffler

Authors
  1. W. Gassmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Haferlach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Schmitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. Kayser
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. H. Euler
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Drews
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Löffler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gassmann, W., Haferlach, T., Schmitz, N. et al. Analyse prognostischer Faktoren beim Plasmozytom. Klin Wochenschr 62, 896–905 (1984). https://doi.org/10.1007/BF01727438

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01727438

Key words

Search

Navigation